These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31489034)

  • 1. Karonudib is a promising anticancer therapy in hepatocellular carcinoma.
    Hua X; Sanjiv K; Gad H; Pham T; Gokturk C; Rasti A; Zhao Z; He K; Feng M; Zang Y; Zhang J; Xia Q; Helleday T; Warpman Berglund U
    Ther Adv Med Oncol; 2019; 11():1758835919866960. PubMed ID: 31489034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation and development of MTH1 inhibitors for treatment of cancer.
    Warpman Berglund U; Sanjiv K; Gad H; Kalderén C; Koolmeister T; Pham T; Gokturk C; Jafari R; Maddalo G; Seashore-Ludlow B; Chernobrovkin A; Manoilov A; Pateras IS; Rasti A; Jemth AS; Almlöf I; Loseva O; Visnes T; Einarsdottir BO; Gaugaz FZ; Saleh A; Platzack B; Wallner OA; Vallin KS; Henriksson M; Wakchaure P; Borhade S; Herr P; Kallberg Y; Baranczewski P; Homan EJ; Wiita E; Nagpal V; Meijer T; Schipper N; Rudd SG; Bräutigam L; Lindqvist A; Filppula A; Lee TC; Artursson P; Nilsson JA; Gorgoulis VG; Lehtiö J; Zubarev RA; Scobie M; Helleday T
    Ann Oncol; 2016 Dec; 27(12):2275-2283. PubMed ID: 27827301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model.
    Moukengue B; Brown HK; Charrier C; Battaglia S; Baud'huin M; Quillard T; Pham TM; Pateras IS; Gorgoulis VG; Helleday T; Heymann D; Berglund UW; Ory B; Lamoureux F
    EBioMedicine; 2020 Mar; 53():102704. PubMed ID: 32151797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Karonudib has potent anti-tumor effects in preclinical models of B-cell lymphoma.
    Oksvold MP; Berglund UW; Gad H; Bai B; Stokke T; Rein ID; Pham T; Sanjiv K; Øy GF; Norum JH; Smeland EB; Myklebust JH; Helleday T; Våtsveen TK
    Sci Rep; 2021 Mar; 11(1):6317. PubMed ID: 33737576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MTH1 as a target to alleviate T cell driven diseases by selective suppression of activated T cells.
    Karsten S; Fiskesund R; Zhang XM; Marttila P; Sanjiv K; Pham T; Rasti A; Bräutigam L; Almlöf I; Marcusson-Ståhl M; Sandman C; Platzack B; Harris RA; Kalderén C; Cederbrant K; Helleday T; Warpman Berglund U
    Cell Death Differ; 2022 Jan; 29(1):246-261. PubMed ID: 34453118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MutT Homolog 1 Inhibitor Karonudib Attenuates Autoimmune Hepatitis by Inhibiting DNA Repair in Activated T Cells.
    Chen Y; Hua X; Huang B; Karsten S; You Z; Li B; Li Y; Li Y; Liang J; Zhang J; Wei Y; Chen R; Lyu Z; Xiao X; Lian M; Wei J; Fang J; Miao Q; Wang Q; Berglung UW; Tang R; Helleday T; Ma X
    Hepatol Commun; 2022 May; 6(5):1016-1031. PubMed ID: 34894107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B Virus X Protein Increases 8-Oxo-7,8-Dihydro-2'-Deoxyguanosine (8-Oxodg) Level via Repressing MTH1/ MTH2 Expression in Hepatocytes.
    Lin YT; Liu W; He Y; Wu YL; Chen WN; Lin XJ; Lin X
    Cell Physiol Biochem; 2018; 51(1):80-96. PubMed ID: 30448843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitotic MTH1 Inhibitors in Treatment of Cancer.
    Helleday T
    Cancer Treat Res; 2023; 186():223-237. PubMed ID: 37978139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptation to Chronic-Cycling Hypoxia Renders Cancer Cells Resistant to MTH1-Inhibitor Treatment Which Can Be Counteracted by Glutathione Depletion.
    Hansel C; Hlouschek J; Xiang K; Melnikova M; Thomale J; Helleday T; Jendrossek V; Matschke J
    Cells; 2021 Nov; 10(11):. PubMed ID: 34831264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of MutT homolog-1 expression on esophageal squamous cell carcinoma.
    Akiyama S; Saeki H; Nakashima Y; Iimori M; Kitao H; Oki E; Oda Y; Nakabeppu Y; Kakeji Y; Maehara Y
    Cancer Med; 2017 Jan; 6(1):258-266. PubMed ID: 27917618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
    Ou DL; Shyue SK; Lin LI; Feng ZR; Liou JY; Fan HH; Lee BS; Hsu C; Cheng AL
    Oncotarget; 2015 Sep; 6(29):27953-65. PubMed ID: 26172295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MTH1 deficiency selectively increases non-cytotoxic oxidative DNA damage in lung cancer cells: more bad news than good?
    Abbas HHK; Alhamoudi KMH; Evans MD; Jones GDD; Foster SS
    BMC Cancer; 2018 Apr; 18(1):423. PubMed ID: 29661172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and function of MutT homolog 1 in distinct subtypes of breast cancer.
    Zhang X; Song W; Zhou Y; Mao F; Lin Y; Guan J; Sun Q
    Oncol Lett; 2017 Apr; 13(4):2161-2168. PubMed ID: 28454376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Birth of MTH1 as a therapeutic target for glioblastoma: MTH1 is indispensable for gliomatumorigenesis.
    Tu Y; Wang Z; Wang X; Yang H; Zhang P; Johnson M; Liu N; Liu H; Jin W; Zhang Y; Cui D
    Am J Transl Res; 2016; 8(6):2803-11. PubMed ID: 27398163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticancer effect of (S)-crizotinib on osteosarcoma cells by targeting MTH1 and activating reactive oxygen species.
    Qing X; Shao Z; Lv X; Pu F; Gao F; Liu L; Shi D
    Anticancer Drugs; 2018 Apr; 29(4):341-352. PubMed ID: 29420337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glioblastoma and glioblastoma stem cells are dependent on functional MTH1.
    Pudelko L; Rouhi P; Sanjiv K; Gad H; Kalderén C; Höglund A; Squatrito M; Schuhmacher AJ; Edwards S; Hägerstrand D; Berglund UW; Helleday T; Bräutigam L
    Oncotarget; 2017 Oct; 8(49):84671-84684. PubMed ID: 29156675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Echinacoside induces apoptotic cancer cell death by inhibiting the nucleotide pool sanitizing enzyme MTH1.
    Dong L; Wang H; Niu J; Zou M; Wu N; Yu D; Wang Y; Zou Z
    Onco Targets Ther; 2015; 8():3649-64. PubMed ID: 26677335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
    Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
    J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma.
    Lai YL; Wang KH; Hsieh HP; Yen WC
    J Biomed Sci; 2022 Jan; 29(1):5. PubMed ID: 35062934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MTH1 favors mesothelioma progression and mediates paracrine rescue of bystander endothelium from oxidative damage.
    Magkouta SF; Pappas AG; Vaitsi PC; Agioutantis PC; Pateras IS; Moschos CA; Iliopoulou MP; Kosti CN; Loutrari HV; Gorgoulis VG; Kalomenidis IT
    JCI Insight; 2020 Jun; 5(12):. PubMed ID: 32554927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.